
    
      To evaluate the longer term safety of lurasidone (20, 40, 60 or 80 mg/day) in subjects with
      bipolar I disorder.

      Subjects will be initially treated with open-label lurasidone 40 mg/day (Day 1).

      Dose adjustment of study drug (20, 40, 60 or 80 mg /day) should occur at the regularly
      scheduled visits and in increments/decrements of 1 dose level.
    
  